Medication info
Empagliflozin/Metformin Sustained-Release Tablets 10/1000 mg

Empagliflozin/Metformin Sustained-Release Tablets 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletEmpagliflozin›10mg / 1 tablet
Manufacturer / importer
Dongwha Pharmaceutical Co., Ltd.
Appearance
Pale pink, bilaterally convex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202500992 · Approved 2025.04.24 · Insurance code 642707820

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be needed based on renal function, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Dongwha Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes with difficulty in blood sugar control
  • cardiovascular disease
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes, in conjunction with diet and exercise. It is particularly administered to patients whose blood sugar is not adequately controlled, and in case of cardiovascular disease, specialist instructions should be followed. This medication effectively aids in controlling blood sugar and helps manage diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg and the patient's current dose of metformin. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment may be needed based on renal function, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used for the treatment of diabetes and helps in controlling blood sugar. When taking this medication, there is a risk of a rare side effect known as severe lactic acidosis, so symptoms must be closely monitored. Lactic acidosis is a condition where there is an excessive buildup of lactic acid in the body, which can be very dangerous. Additionally, caution is required when taken with insulin or sulfonylurea medications due to the risk of hypoglycemia. Patients with impaired kidney function, acute kidney problems, serious infections, congestive heart failure, acute myocardial infarction, or other specific health conditions should not take this medication. The use of iodine contrast agents before and after examinations requires temporary cessation of this medication, and it should be restarted only after kidney function has been confirmed as normal. Women who are pregnant or might become pregnant, patients with liver dysfunction, and patients who are in very poor nutritional status are also advised not to use this medication. During treatment, side effects such as hypoglycemia, urinary tract infections, genitourinary infections, increased urination, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, constipation, reduced and deficient vitamin B12 levels, taste disturbances, itching, rashes, abnormal liver function tests, hepatitis, urinary difficulties, interstitial nephritis, thirst, increased serum lipids, increased blood creatinine/decreased glomerular filtration rate, increased hematocrit, weight loss, lumbar pain, headaches, dizziness, insomnia, nausea, and gastritis may occur, so symptoms should be closely monitored. Especially for elderly patients aged 75 and older, there is an increased risk of fluid loss, so careful administration is required. This medication should be swallowed whole without breaking or chewing, and the tablet shell may pass in the stool, which is normal. Additionally, alcohol consumption may increase the risk of lactic acidosis, so alcohol should be avoided during treatment. Regular monitoring of kidney function and serum vitamin B12 levels during the use of this medication is recommended. If any abnormal symptoms or discomfort occur, consultation with a physician should be sought immediately, and prompt treatment is necessary in case of emergency.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • perineal necrosis
  • ketoacidosis
  • decreased fluid volume
  • nausea
Show 183 more
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • angioedema
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • reduced and deficient vitamin B12
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureteral stones
  • acute kidney injury
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • posterior retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • moist cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • limb injury
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • spleen injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • diarrhea
  • dyspepsia
  • abdominal pain
  • nausea
  • gastritis
  • gastrointestinal disorders
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • low back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale pink, bilaterally convex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.